Welcome to our dedicated page for Ceribell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
CeriBell Inc insider Joseph Taylor filed to potentially sell shares of the company’s common stock. The notice lists up to 300,000 common shares to be sold through Sanford C. Bernstein & Co., LLC on or after August 13, 2026, with trading on Nasdaq. It also identifies common shares received as compensation from grants dated April 22, 2021 and August 14, 2018, totaling 3,204 and 13,064 shares, respectively, as securities to be sold for cash. In addition, the filing reports that during the past three months, on June 11, 2026, Taylor sold 5,500 common shares for proceeds of $101,255.00.
Ceribell, Inc. reported strong top-line growth but continued losses for the quarter and six months ended June 30, 2026. Total revenue rose to $28.1 million for the quarter and $54.6 million year-to-date, up 33% and 31% from 2025, driven by higher sales of disposable EEG Wearables and subscription fees as adoption expanded to more than 700 hospitals.
Gross margin improved to 92% in the quarter and 90% year-to-date, helped by scale and a $1.6 million IEEPA tariff refund. Operating expenses grew 36% year-to-date to $89.8 million, mainly from increased headcount, commercialization, and IP-related legal costs, leading to a net loss of $19.3 million for the quarter and $39.0 million year-to-date. The company held $129.3 million in cash, cash equivalents, and marketable securities and believes this will fund operations for at least 12 months. Subsequent to quarter-end, Ceribell refinanced its term loan with a new credit facility that includes a $30 million term loan commitment and a revolving line initially sized at $20 million, of which $20 million was drawn to repay the prior facility.
Ceribell, Inc. reported strong top-line growth for the quarter ended June 30, 2026. Total revenue was $28.1 million, up 33% from $21.2 million a year earlier, driven by new account additions and higher utilization across its installed base. Product revenue reached $21.2 million and subscription revenue $6.9 million, both rising about 30% year over year. The company ended the quarter with 712 active accounts.
Profitability remains negative but margins are high. Gross profit was $25.9 million with a 92% gross margin, aided by manufacturing efficiencies, a new Vietnam line, and one-time tariff refunds. Operating expenses increased 37% to $45.9 million as Ceribell invested in commercial expansion, R&D, and legal costs. Net loss widened to $19.3 million, or $0.51 per share, while Adjusted EBITDA loss was $9.8 million.
The balance sheet showed $129.3 million in cash, cash equivalents, and marketable securities at June 30, 2026. Ceribell subsequently entered a new credit facility providing access to up to $60 million in committed capital. The company raised its 2026 revenue outlook to $114–$117 million, implying about 28–31% growth. It also highlighted multiple FDA 510(k) clearances and a CMS New Technology Add-On Payment for its delirium monitoring solution, effective October 1, 2026.
FMR LLC filed an amended Schedule 13G reporting beneficial ownership of common stock of Ceribell Inc. FMR LLC and Abigail P. Johnson each report beneficial ownership of 5,691,393.03 shares, representing 15.0% of Ceribell’s common stock.
FMR LLC reports 5,688,542 shares with sole voting power and 5,691,393.03 shares with sole dispositive power, with no shared voting or dispositive power. One or more other persons may receive dividends or sale proceeds, but no such person has more than five percent of the class.
Ceribell, Inc. President and CEO Chao Xingjuan exercised stock options covering 25,000 shares of common stock at an exercise price of $4.70 per share and sold 39,000 common shares at a weighted average price of $18.32, in multiple trades between $17.88 and $18.72, pursuant to a Rule 10b5-1 trading plan.
An entity associated with her, the ACP 2021 Trust, holds 369,088 shares; she may be deemed to share beneficial ownership of these securities but disclaims beneficial ownership except to the extent of her pecuniary interest.
Xingjuan Chao filed a notice of intent to sell 39,000 shares of common stock of CBLL through Fidelity Brokerage Services, with an aggregate market value of $702,000.00. The filing notes total common shares outstanding of 37,942,700 and links the sale to stock option exercises.
Over the prior three months, Chao reported multiple sales of common stock, including 39,000 shares for $784,000.03, 6,030 shares for $108,515.27, 39,000 shares for $714,855.81, and 39,000 shares for $776,162.92, as well as option exercises for 14,000 and 25,000 shares.
Ceribell, Inc. filed an initial statement of beneficial ownership for Thomas A. West, identifying him as a director of the company. He is not listed as an officer or a ten percent owner in this filing.
This submission reports no insider transactions and notes an exhibit titled Power of Attorney authorizing certain filing actions.
West Thomas A. reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. director Thomas A. West received an equity grant of 16,011 shares of Common Stock in the form of restricted stock units (RSUs) on 2026-07-28. The award was reported at a per-share price of $0.00, and his directly held position after this grant is 16,011 shares, all from this RSU award.
O'KEEFE SHARON reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. director Sharon O'Keefe received a grant of 16,011 restricted stock units (RSUs) representing common stock on July 28, 2026. The award was reported at a price of $0.00 per unit and results in total direct holdings of 16,011 RSUs after the transaction.
Ceribell, Inc. filed an initial Form 3 identifying Sharon O’Keefe as a director. The filing lists her as a reporting person under SEC beneficial ownership rules but shows no insider transactions or derivative positions and does not disclose any specific share holdings.